"Patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis present miRNA profiles in urinary extracellular vesicles associated with disease progression" was the awarded work.

So far, 240 volunteers have been recruited within all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.

These results reinforce the need for more individualized attention to address educational needs from an early stage.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

Researchers at the VHIR have carried out a study showing that the ClC-5 protein regulates collagen levels through the β-catenin pathway and lysosomal degradation.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

The study, in which Vall d'Hebron participates, helps to understand the variability among patients with retinitis pigmentosa.

La iniciativa "Sin Piedad" explica la història d'en David, un nen que s'està tractant d'un càncer pediàtric, un exemple d'actitud lluitadora davant la malaltia.

The money will allow research into paediatric nervous system tumours and childhood sarcomas to continue, with the aim of improving children's chances of survival and reducing the side effects of treatment.

The association makes the fifth annual donation of 52,390€ that will finance a project to study new therapies for this childhood tumor.

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

The study, which is part of the European RECOMB project, is currently recruiting volunteers.

This clinical trial is part of the European project RBDCOV, led by HIPRA in which Vall d'Hebron participates, whose recruitment is still open.

The meeting has been the meeting point of the EpSSG group dedicated to research to improve the treatment of childhood and adolescent soft tissue sarcomas.

‘RBDCOV Talks' brings vaccine clinical research closer to the general audience through a podcast series with 10 scientists, clinicians, specialists and community advocates who are partners in the project.

The funds will enable the recruitment and retention of young talent, as well as the development of a new epigenetic drug

The initiative, coordinated by Dr. Pablo Velasco and Dr. Jose Luis Fuster, aims to bring innovation closer to patients and promote research projects in this disease.

The project aims to test the HIPRA vaccine against COVID-19 in children (including adolescents) and immunocompromised people.

The meeting, in which Dr. Pere Soler participated, showed the results of the first year with the description of new genetic defects associated with severe forms of COVID-19 and novelties in the detection of autoantibodies against interferons.

The platform offers health workers the latest information on infectious and tropical diseases and also serves as a training tool.

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

This initiative has several collaborative projects with the aim of increasing knowledge about rare blood diseases and improving patient care.

The multicenter phase 1 trial has been conducted in patients aged 2 to 21 years with solid tumors unresponsive to standard treatments or in relapse.